Clinical Trial Update: Efficacy and Safety of Buspirone, Sustained-release Tablets, 15 mg in Patients With Autonomic Dysfunction Syndrome Accompanied by Vertigo [Phase 3]

View source ↗

Summary

Phase 3 trial update evaluating efficacy and safety of sustained-release buspirone 15 mg in patients with autonomic dysfunction syndrome accompanied by vertigo.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autonomic Dysfunction
• Vertigo

Drugs mentioned

• Buspirone sustained-release 15 mg (buspirone)

Snippet

Sponsor: Valenta Pharm JSC | Conditions: Vertigo, Autonomic Dysfunction | Phase 3 | Status: COMPLETED